Aardvark Therapeutics, Inc. Common Stock (AARD) NASDAQ
4.54
+0.03(+0.67%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.54
+0.03(+0.67%)
Currency In USD
| Previous Close | 4.51 |
| Open | 4.5 |
| Day High | 4.8 |
| Day Low | 4.35 |
| 52-Week High | 17.94 |
| 52-Week Low | 3.35 |
| Volume | 136,890 |
| Average Volume | 307,254 |
| Market Cap | 99.05M |
| PE | -1.41 |
| EPS | -3.21 |
| Moving Average 50 Days | 4.83 |
| Moving Average 200 Days | 10.03 |
| Change | 0.03 |
Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome
GlobeNewswire Inc.
Feb 27, 2026 9:05 PM GMT
SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Feb 13, 2026 1:00 PM GMT
SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the
Aardvark Therapeutics Announces Leadership Appointments
GlobeNewswire Inc.
Feb 12, 2026 1:00 PM GMT
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the